Metsera Inc (MTSR) Stock Price, Quote & News

Company Profile

Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity, as well as MET-815i to reduce weight or prevents weight gain. The company was incorporated in 2022 and is based in New York, N...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 784 6595

Website: metsera.com

Address:

3 World Trade Center, 175 Greenwich Street, New York, United States

PrivateProfiteersAnalyst Dec. 25 at 2:46 PM

Actionable Trade Alert for $MTSR: Market Context: $MTSR is currently trading near its 60D high of $70.76, indicating bullish momentum. The price is also above the 60D low of $70.13, suggesting a potential upward trend. Directional Bias: Given the proximity to the 60D high, there is a bullish bias. Without RSI and moving averages, we rely on price action, which shows a tight range. A breakout above $70.76 could signal further upward movement. Suggested Entry: Consider entering a long position at $70.60. Stop Loss: Set a stop loss at $70.00 to limit potential losses. Take Profit Targets: 1. Target 1: $71.50 (1.27% gain) 2. Target 2: $72.00 (2.10% gain) 3. Target 3: $73.00 (3.52% gain) Achieving the third target would yield an ROI of approximately 17.5%. Monitor price action closely for any changes in momentum. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

0 · Reply

FingerlessRage Dec. 24 at 12:50 PM

$MTSR I LIKE IT

1 · Reply

Thepatientone Dec. 23 at 9:34 PM

$ALT BIC vs $AKRO , $ETNB , $MTSR , $MADRIG, $VKTX Altimmune is not “missing” anything. It has already cleared the Phase 3 gate and is now running a program that reflects modern regulatory thinking, not legacy dogma. None of the others have done such, no one.

2 · Reply

Tradinggraces17 Dec. 23 at 8:49 PM

$ALT $ETNB $MDGL $MTSR $VKTX As we kick off Festivus 2025, I’d like to start with the Airing of Grievances. No one in VKTX gives a shit about ALT, and it being BIC. No one. That’s all, carry on.

3 · Reply

Thepatientone Dec. 23 at 8:33 PM

$ALT BIC vs $AKERO, $ETNB , $MTSR , $MDGL , $VKTX and etc. Please mute parasites and leaches. Do your DD and think. Wegovy/Ozempic were approved for what? diabetes, the weight loss was a side effect and it is not a quality weight loss, muscle mass preservation is critical to long term health. FDA does not care about the margins, cares about safety, Pemvi is BIC, cares about titration so patients will stay on the drug, Pemvi is best in class, cares about side effects, Pemvi has none. BIC and Pemvi is for Mash resolution, which is BIC in just 24 weeks, Fibrosis non worsening is an FDA requirement not fibrosis clearance so BIC again. Then in addition you have the CV improvements and NITs showing BIC platform. Rely on facts only facts. In a matter of week/s you will be happy.

3 · Reply

judgeyoung2 Dec. 20 at 10:38 PM

$MTSR j

0 · Reply

Thepatientone Dec. 20 at 5:45 PM

$ALT BIC VS $AKRO , $89BIO, $MTSR , $MDGL , $VKTX Quality of weight loss: Yes (likely), subject to continued validation MASH resolution at 24 weeks: Yes (strong case) Cardiovascular health: Not proven yet (credible thesis, but still optionality) Tolerability / AE / discontinuations: Yes (strong case) NITs: Yes (strong case for coherence + durability) The one thing I’d add (even though you didn’t ask) If you’re comparing “superior treatment” in the full MASH regulatory sense, the open question remains: Biopsy-confirmed fibrosis improvement in a Phase 3-sized dataset at 48–52 weeks (and durability beyond)

0 · Reply

Thepatientone Dec. 20 at 2:47 PM

$ALT BIC vs $AKERO, $ETNB , $MTSR , $MDGL , $VKTX - AI read and NITs will be the standard and $ALT is leading. KOLs are not wrong when they say biopsy can miss or misclassify disease. 1️⃣ Sampling error (the biggest problem) A biopsy samples ~1/50,000 of the liver Fibrosis and inflammation are heterogeneous One core can show F2, another F3 or F1 in the same patient Studies show: 20–30% discordance in fibrosis staging between two biopsy samples from the same liver Inter-reader variability even among expert pathologists 👉 This means biopsy can both overestimate and underestimate response. 2️⃣ Noise overwhelms signal in short trials Fibrosis remodeling is slow 24–52 weeks is often borderline too short to see clean stage shifts A true biological improvement may not cross the ≥1-stage threshold because of: Baseline misclassification Borderline staging Patchy regression This is why KOLs often say: “The drug worked, but the biopsy couldn’t see it.”

1 · Reply

SimpleWinningSetups Dec. 19 at 8:52 PM

Hedge Alert Live - Protect Your Portfolio Contract: $MTSR $70.00 Put · DEC 19, 2025 Exp Entry Price: $4.35 - $4.57 Exit Price Target: $8.09 Profit Margin: +86% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

PrivateProfiteersAnalyst Dec. 19 at 4:41 PM

Actionable Trade Alert for $MTSR: Market Context: $MTSR is currently trading near its 60D high of $70.76, indicating potential resistance. The price is within a tight range between the 60D high and low of $70.76 and $70.13, suggesting a consolidation phase. Directional Bias: Given the proximity to the 60D high, there is a bullish bias if the price breaks above this level. The lack of RSI and moving averages data limits the analysis, but the recent price action indicates strength. Trade Plan: - Suggested Entry: $70.76 (breakout above the 60D high) - Stop Loss: $70.13 (just below the 60D low) - Take Profit Targets: 1. $72.00 (3.5% gain) 2. $73.50 (9.5% gain) 3. $82.50 (17% gain) This plan allows for a solid risk-reward ratio with a stop loss of about 0.9% and a potential return of 17% on the final target. Monitor the breakout closely for entry confirmation. For more insights, visit https://privateprofiteers.com. https://privateprofiteers.com

0 · Reply

Market Cap	7.42B
Revenue (ttm)	0.00
Net Income (ttm)	-209.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	27,908,900
Avg Vol	3,697,740
Day's Range	N/A - N/A
Shares Out	105.29M
Stochastic %K	43%
Beta	N/A
Analysts	Strong Sell
Price Target	$55.75